Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 ...
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
By Sriparna Roy April 17 (Reuters) - Eli Lilly's newly launched weight-loss pill was prescribed 1,390 times in the U.S. in ...
A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial ...
Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for liver ...
Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized ...
Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized ...
Viking's candidate is part of the GLP-1 class of drugs, which interact with hormonal pathways controlling appetite and blood ...
Incretin-based obesity medications may result in higher muscle-related loss vs. other weight loss strategies, according to ...
April 16 () - Eli Lilly said on Thursday its newly approved obesity pill helped reduce the risk of major cardiovascular ...
New research reveals that obesity affects men and women in surprisingly different ways. Men are more likely to develop harmful abdominal fat and signs of liver stress, while women show higher ...
Louisiana lawmakers debated a bill that would require Medicaid to cover FDA-approved weight-loss medications for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results